|
Product Name: Cancer of Unknown Primary
Product Description
It is estimated that in 2006, approximately 107,000 new cases of colon cancer and 42,000 new cases of rectal cancer will be diagnosed in the U.S., and about 55,000 people will die of these diseases. Evidence from several studies indicates that screening for, detecting and removing colorectal cancers and pre-cancerous adenomatous polyps can significantly reduce colon cancer incidence and colon cancer-related mortality as reviewed by the U.S. Preventative Services Task Force in their publication in the Annals of Internal Medicine in 2002. In the U.S., routine tests for the early detection of colon cancer are recommended for every person aged 50 and older.
Current diagnostic tests - The current standard screening methods for colorectal cancer include colonoscopy and the fecal occult blood tests. Both tests, however, suffer from serious disadvantages. The colonoscopy test is effective, but many people are hesitant to have this procedure due to its high cost, high discomfort and its potential for more significant side effects. The fecal occult blood test, on the other hand, is a simple and cheap test, but is relatively inaccurate.
Currently the standard of care for colorectal cancer includes adjuvant chemotherapy, although only a minor percentage of patients benefit from this treatment. Early-stage colorectal cancer patients are faced with the decision of whether or not to use chemotherapy after surgery as well as which chemotherapy to use. There is currently no effective test that can help these patients and their doctors make this important decision. Therefore, there is also a significant unmet need to identify patients who will benefit from chemotherapy.
Our strategy - We are currently seeking to address these market needs by identifying a panel of biomarkers based on microRNAs. Our scientists have already identified microRNAs which are differentially expressed in healthy and tumor tissues, and are continually analyzing additional samples.
Company Details
Rosetta Genomics is an international leader in diagnostic and therapeutic product development and medical research involving micro-ribonucleic acid, commonly known as microRNA. Rosetta has developed an extensive integrated platform in microRNA... more
| More Products of this Company: |
Breast cancer, Colorectal cancer, Infectioous Deseases, Liver cancer, Lung cancer, MicroRNA-Based Cancer Diagnostic Products, MicroRNAs and Therapeutic Products, Prostate cancer |
| Related Products: |
Breast cancer, Colorectal cancer, ESGRO Complete™ Clonal Grade Medium, Infectioous Deseases, Liver cancer, Lung cancer, MicroRNA-Based Cancer Diagnostic Products, MicroRNAs and Therapeutic Products, Prostate cancer |
|
